AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
Authors: Kuehl, P Zhang, J Lin, Y Lamba, J Assem, M Schuetz, J Watkins, PB Daly, A Wrighton, SA Hall, SD Maurel, P Relling, M Brimer, C Yasuda, K Venkataramanan, R Strom, S Thummel, K Boguski, MS Schuetz, E
Citation: P. Kuehl et al., Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, NAT GENET, 27(4), 2001, pp. 383-391
Application of in silico approaches to predicting drug-drug interactions
Authors: Ekins, S Wrighton, SA
Citation: S. Ekins et Sa. Wrighton, Application of in silico approaches to predicting drug-drug interactions, J PHARM TOX, 45(1), 2001, pp. 65-69
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants
Authors: Zhang, J Kuehl, P Green, ED Touchman, JW Watkins, PB Daly, A Hall, SD Maurel, P Relling, M Brimer, C Yasuda, K Wrighton, SA Hancock, M Kim, RB Strom, S Thummel, K Russell, CG Hudson, JR Schuetz, EG Boguski, MS
Citation: J. Zhang et al., The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants, PHARMACOGEN, 11(7), 2001, pp. 555-572
Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine
Authors: Ring, BJ Eckstein, JA Gillespie, JS Binkley, SN Vandenbranden, M Wrighton, SA
Citation: Bj. Ring et al., Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine, J PHARM EXP, 297(3), 2001, pp. 1044-1050
Progress in predicting human ADME parameters in silico
Authors: Ekins, S Waller, CL Swaan, PW Cruciani, G Wrighton, SA Wikel, JH
Citation: S. Ekins et al., Progress in predicting human ADME parameters in silico, J PHARM TOX, 44(1), 2000, pp. 251-272
Present and future in vitro approaches for drug metabolism
Authors: Ekins, S Ring, BJ Grace, J McRobie-Belle, DJ Wrighton, SA
Citation: S. Ekins et al., Present and future in vitro approaches for drug metabolism, J PHARM TOX, 44(1), 2000, pp. 313-324
Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank
Authors: Fisher, MB VandenBranden, M Findlay, K Burchell, B Thummel, KE Hall, SD Wrighton, SA
Citation: Mb. Fisher et al., Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank, PHARMACOGEN, 10(8), 2000, pp. 727-739
A population approach to enzyme characterization and identification: Application to phenacetin O-deethylation
Authors: Belle, DJ Ring, BJ Allerheiligen, SRB Heathman, MA O'Brien, LM Sinha, V Roskos, LK Wrighton, SA
Citation: Dj. Belle et al., A population approach to enzyme characterization and identification: Application to phenacetin O-deethylation, PHARM RES, 17(12), 2000, pp. 1531-1536
The human CYP3A subfamily: Practical considerations
Authors: Wrighton, SA Schuetz, EG Thummel, KE Shen, DD Korzekwa, KR Watkins, PB
Citation: Sa. Wrighton et al., The human CYP3A subfamily: Practical considerations, DRUG METAB, 32(3-4), 2000, pp. 339-361
Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors
Authors: Ekins, S Bravi, G Binkley, S Gillespie, JS Ring, BJ Wikel, JH Wrighton, SA
Citation: S. Ekins et al., Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors, DRUG META D, 28(8), 2000, pp. 994-1002
In vitro glucuronidation using human liver microsomes and the pore-formingpeptide alamethicin
Authors: Fisher, MB Campanale, K Ackermann, BL Vandenbranden, M Wrighton, SA
Citation: Mb. Fisher et al., In vitro glucuronidation using human liver microsomes and the pore-formingpeptide alamethicin, DRUG META D, 28(5), 2000, pp. 560-566
Short-term treatment with alcohols causes hepatic steatosis and enhances acetaminophen hepatotoxicity in Cyp2e1(-/-) mice
Authors: Sinclair, JF Szakacs, JG Wood, SG Walton, HS Bement, JL Gonzalez, FJ Jeffery, EH Wrighton, SA Bement, WJ Sinclair, PR
Citation: Jf. Sinclair et al., Short-term treatment with alcohols causes hepatic steatosis and enhances acetaminophen hepatotoxicity in Cyp2e1(-/-) mice, TOX APPL PH, 168(2), 2000, pp. 114-122
The effect of hormone replacement therapy on CYP3A activity
Authors: Gorski, JC Wang, ZQ Heahner-Daniels, BD Wrighton, SA Hall, SD
Citation: Jc. Gorski et al., The effect of hormone replacement therapy on CYP3A activity, CLIN PHARM, 68(4), 2000, pp. 412-417
Lack of correlation between in vitro and in vivo studies on the effects oftangeretin and tangerine juice on midazolam hydroxylation
Authors: Backman, JT Maenpaa, J Belle, DJ Wrighton, SA Kivisto, KT Neuvonen, PJ
Citation: Jt. Backman et al., Lack of correlation between in vitro and in vivo studies on the effects oftangeretin and tangerine juice on midazolam hydroxylation, CLIN PHARM, 67(4), 2000, pp. 382-390
Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases - Comparison of human liver and kidney microsomes and mammalianenzymes
Authors: Hamman, MA Haehner-Daniels, BD Wrighton, SA Rettie, AE Hall, SD
Citation: Ma. Hamman et al., Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases - Comparison of human liver and kidney microsomes and mammalianenzymes, BIOCH PHARM, 60(1), 2000, pp. 7-17
Acetaminophen hepatotoxicity precipitated by short-term treatment of rats with ethanol and isopentanol - Protection by triacetyloleandomycin
Authors: Sinclair, JF Szakacs, JG Wood, SG Kostrubsky, VE Jeffery, EH Wrighton, SA Bement, WJ Wright, D Sinclair, PR
Citation: Jf. Sinclair et al., Acetaminophen hepatotoxicity precipitated by short-term treatment of rats with ethanol and isopentanol - Protection by triacetyloleandomycin, BIOCH PHARM, 59(4), 2000, pp. 445-454
Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millennium
Authors: Ekins, S Ring, BJ Bravi, G Wikel, JH Wrighton, SA
Citation: S. Ekins et al., Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millennium, IUL BIOTECH, 2, 2000, pp. 269-299
Evaluation of an in vitro coculture model for the blood-brain barrier: Comparison of human umbilical vein endothelial cells (ECV304) and rat glioma cells (C6) from two commercial sources
Authors: Scism, JL Laska, DA Horn, JW Gimple, JL Pratt, SE Shepard, RL Dantzig, AH Wrighton, SA
Citation: Jl. Scism et al., Evaluation of an in vitro coculture model for the blood-brain barrier: Comparison of human umbilical vein endothelial cells (ECV304) and rat glioma cells (C6) from two commercial sources, IN VITRO-AN, 35(10), 1999, pp. 580-592
Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors
Authors: Ekins, S Bravi, G Binkley, S Gillespie, JS Ring, BJ Wikel, JH Wrighton, SA
Citation: S. Ekins et al., Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors, PHARMACOGEN, 9(4), 1999, pp. 477-489
The role of CYP2B6 in human xenobiotic metabolism
Authors: Ekins, S Wrighton, SA
Citation: S. Ekins et Sa. Wrighton, The role of CYP2B6 in human xenobiotic metabolism, DRUG METAB, 31(3), 1999, pp. 719-754
Predicting drug interactions and pharmacokinetic variability with in vitromethods: The olanzapine experience
Authors: Wrighton, SA Ring, BJ
Citation: Sa. Wrighton et Bj. Ring, Predicting drug interactions and pharmacokinetic variability with in vitromethods: The olanzapine experience, DRUG METAB, 31(1), 1999, pp. 15-28
The use of human hepatocyte cultures to study the induction of cytochrome P-450
Authors: Kostrubsky, VE Ramachandran, V Venkataramanan, R Dorko, K Esplen, JE Zhang, SM Sinclair, JF Wrighton, SA Strom, SC
Citation: Ve. Kostrubsky et al., The use of human hepatocyte cultures to study the induction of cytochrome P-450, DRUG META D, 27(8), 1999, pp. 887-894
Flavin-containing monooxygenase-mediated N-oxidation of the M-1-muscarinicagonist xanomeline
Authors: Ring, BJ Wrighton, SA Aldridge, SLK Hansen, K Haehner, B Shipley, LA
Citation: Bj. Ring et al., Flavin-containing monooxygenase-mediated N-oxidation of the M-1-muscarinicagonist xanomeline, DRUG META D, 27(10), 1999, pp. 1099-1103
Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily
Authors: Gorski, JC Jones, DR Hamman, MA Wrighton, SA Hall, SD
Citation: Jc. Gorski et al., Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily, XENOBIOTICA, 29(9), 1999, pp. 931-944
Effect of arsenite on induction of CYP1A, CYP2B, and CYP3A in primary cultures of rat hepatocytes
Authors: Jacobs, JM Nichols, CE Andrew, AS Marek, DE Wood, SG Sinclair, PR Wrighton, SA Kostrubsky, VE Sinclair, JF
Citation: Jm. Jacobs et al., Effect of arsenite on induction of CYP1A, CYP2B, and CYP3A in primary cultures of rat hepatocytes, TOX APPL PH, 157(1), 1999, pp. 51-59
Risultati: 1-25 | 26-33